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Methsuximide therapy of juvenile myoclonic 
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DANIEL L. HURST 
Department of Neurology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA 
Currently valproic acid is considered to be the drug of first choice for juvenile myoclonic epilepsy (JME) resulting 
in a 70-90% control rate for all seizure types associated with JME. In those situations where valproic acid fails to 
control seizure activity, results in unacceptable side-effects, or is declined due to potential side-effects, an 
alternative ffective monotherapy would be desirable. Five adolescent female patients were placed on meth- 
suximide for JME. All five patients have been seizure free with the use of methsuximide and four out of five are 
now on methsuximide monotherapy with good success. C.L. has now had complete seizure control on 
methsuximide monotherapy, a total of 1200 mg a day, for 7 years with the exception of one seizure vent occurring 
on an attempted discontinuation f methsuximide after being 5 years seizure free. Methsuximide monotherapy as
demonstrated in these five patients is an effective treatment for JME. 
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INTRODUCTION 
Juvenile myoclonic epilepsy (JME) is an epileptic 
syndrome which in most cases has the onset 
during adolescence of the following three seizure 
types: (1) myoclonic jerks, frequently bilateral 
involving both arms, predominantly seen upon 
awakening in the morning; (2) tonic clonic events 
frequently in association with myoclonic jerks; 
and (3) infrequent absence episodes ~-5. Prior to 
the introduction of valproic acid for the treatment 
of JME, a variety of other medications were used 
with only partial Success  6"7. With the introduction 
of valproic acid a high percentage, approximately 
70-90%, of patients with JME have seizure 
control 3"8. Some patients fail to have their 
seizures controlled related to side effects from 
valproic acid 9. Particularly in adolescent females, 
weight gain may be a problem with valproic acid 
resulting in its discontinuation ~°. When valproic 
acid monotherapy fails to achieve complete 
seizure control, other anticonvulsants may be 
added in a two drug combination. Methsuximide 
presents a unique anticonvulsant profile which 
potentially would allow for the treatment of JME 
in monotheraphy. Methsuximide is known to 
treat all three seizure types seen in JME ~ ~-~3. Five 
patients are presented who have had meth- 
suximide used in monotherapy for the treatment 
of JME. 
METHOD 
All medical records in the Texas Tech University 
Health Sciences Center Neurology Clinic were 
reviewed for a diagnosis of JME and treatment 
with methsuximide. This was a retrospective 
review covering a period of nine years. Inclusion 
criteria for the diagnosis of JME were typical case 
histories, an established clinical diagnosis of JME, 
and supportive EEG data. Supportive EEG data 
included (1) normal background activity, and (2) 
generalized polyspike-wave complexes, (3) 4-  
6 Hz generalized spike wave activity, (4) 3 Hz 
generalized spike wave activity, or (5) irregular 
spike wave complexes. 
RESULTS 
Five females with JME on methsuximide were 
identified. Four out of the five are currently on 
methusximide monotheraphy. One individual is 
on  treatment with valproic acid in addition to 
methsuximide, but in the past had been treated 
successfully with methsuximide monotherapy. 
The therapeutic approach was changed in this 
individual due to a complaint of sedation. The 
patient felt the combination of valproic acid, 
which failed in monotherapy, with methsuximide 
gave satisfactory seizure control with fewer 
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side-effects. These five patients are being con- 
tinued on methsuximide long-term (see Table 1). 
At this time all five patients are under good 
seizure control. 
CASE HISTORY 
C.L. is now a 22-year-old female. She was first 
seen at the age of 13 years for a history of having 
had two tonic-clonic seizure events lasting 
approximately 5 minutes each. Her initial seizure 
manifestation occurred 3 months earlier, at which 
time she was noted to have bilateral jerks of her 
arms in the morning which caused her to drop 
whatever she was holding. She was described as 
alert and able to talk during these episodes. Her 
second tonic-clonic seizure, occurring 2 days 
prior to her initial evaluation, was preceded by 
bilateral arm jerks during which she stated, 'Oh, 
Mom, I can't stop them from shaking' and then 
proceeded directly into a tonic-clonic seizure. 
The patient's past medical history was unremark- 
able. Family history was significant for a 20-year- 
old female sibling with epilepsy. Review of 
systems was otherwise unremarkable. Her neuro- 
logic examination was normal. An EEG was 
obtained and showed a generalized spike wave 
discharge at 5 Hz. A CT scan with and without 
contrast was normal. She was given a diagnosis of 
JME and methsuximide, 750mg per day, was 
started. This resulted in a normethsuximide l vel 
of 16/zg/ml; therapeutic range 10-40/zg/ml. 
When a few further myoclonic jerks were noted, 
the dosage was increased to 1200mg a day, 
resulting in a normethsuximide level of 30/,tg/ml. 
After five years of complete seizure control on 
methsuximide, a follow up EEG was obtained 
which was normal and the patient began a slow 
taper off methsuximide. After being completely 
off methsuximide for two weeks, the patient had a 
tonic clonic seizure lasting approximately 30 
seconds. The patient denied any illness at the 
time of the seizure but reported the increased 
stress of final exams. The methsuximide was 
restarted at 1200mg a day and the patient has 
been completely seizure free since that time (for 2 
years). Current plans are to continue the meth- 
suximide as prescribed for an indefinite time 
period. 
DISCUSSION 
Methsuximide is primarily considered a second 
line anticonvulsant for absence pilepsy because 
ethosuximide is more effective than meth- 
suximide in the treatment of absence seizures t4. 
Methsuximide, however, has a wider spectrum of 
anti-seizure activity than ethosuximide'~"2 
Methsuximide is an effective adjunctive therapy 
for other generalized epilepsies, particularly in 
combination with valproic acid ~5. Methsuximide 
has also been documented to be successful in 
controlling myoclonic epilepsy or myoclonic 
atonic seizures in some patients ~3't~'~7. 
Valproic acid is the only currently marketed 
anticonvulsant which is considered both safe and 
effective in controlling all the individual seizure 
types, namely, generalized tonic-clonic, myo- 
clonic, and absence seizures seen in JME ~s-2°. 
Therefore, it is not surprising that valproic acid 
has been found to be an effective treatment for 
JME as an epilepsy syndrome 2'. Those anticon- 
vulsants which treat partial and tonic-clonic 
seizures alone fail to address the myoclonic and 
absence components of JME. Likewise those 
medications, such as clonazepam and tri- 
methadione, which treat absence and myoclonic 
seizures but do not control primary generalized 
tonic clonic seizures, are not effective as 
monotherapy 2''22. An additional effective medi- 
cation for treatment of JME, either in mono- 
therapy or as an adjunctive to valproic acid would 
be very desirable. Currently no series has been 
Table 1: Patient treatment group 
Patients l 2 3 4 5 
Age 17 years 23 years 22 years 25 years 16 years 
Sex female female female female female 
JME onset 12 years 15 years 13 years 15 years 12 years 
Seizure type M, A, T M, A, T M, T M, A, T M, A, T 
EEG pS&W. pS&W pS&W 3HzS&W 5HzS&W 
Rx MS MS, VA MS MS MS 
Dose 1 200 1 050 I 200 900 900 
Seizure free 2 years 3 years 6 years 6 months 6 months 
M, Myoclonic seizures; A, absence seizures; T, tonic-clonic seizures; MS, methsuximide: VA, 
valproic acid; pS & W, polyspike and wave: S & W, Spike and wave. 
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published which has used methsuximide as 
monotherapy for the treatment of JME. 
The five patients presented with JME all have 
shown good responses to treatment with meth- 
suximide resulting in complete seizure control on 
monotherapy in four out of five without sig- 
nificant side-effects As demonstrated in C.L., 
methsuximide both can and did result in long 
term seizure control. The benefit in C.L. to 
methsuximide was readily demonstra'ted when 
she had a generalized but short tonic-clonic 
seizure 2 weeks off of treatment. Patient 1 initially 
presented with only myoclonic jerks and was 
treated with clonazepam with good control of 
myoclonic episodes but not of subsequent onic- 
clonic events. When offered a treatment choice 
between methsuximide and valproic acid, the 
patient and her family elected to use meth- 
suximide over valproate due to concerns about 
potential side effects. Patient 2 was initially 
started on valproic acid which failed to com- 
pletely control the patient's seizures resulting in a 
change to treatment with methsuximide. The 
patient was controlled on methsuximide mono- 
therapy but complained about mild sedation. She 
requested a reduction in her dose and myoclonic 
seizure activity returned. The patient then elected 
to use a combination of valproic acid and 
methsuximide in the hope that lower doses of 
both medications would be able to control her 
seizures in combination without side-effects. 
Patient 4 was initially treated with valproic acid 
but she discontinued on her own the valproic acid 
due to weight gain and multiple other complaints 
to include headaches and dizziness. She was 
started on methsuximide with resulting good 
seizure control. Patient 5 was started on valproic 
acid, but due to weight gain and hair loss, she 
requested a change of medication. She was 
switched to felbamate but subsequently was 
withdrawn due to concerns about serious idiosyn- 
cratic side-effects and a previous history of 
idiopathic thrombocytopenia. The patient is 
currently using methsuximide with no clinical 
side-effects. 
In JME methsuximide can be used as an 
effective alternative monotherapy to valproic 
acid. Individual patients may even prefer meth- 
suximide over valproic acid for treatment of JME, 
as did C.L. Methsuximide is currently an avail- 
able and marked anticonvulsant and presents an 
acceptable side-effect risk profile for use in 
JME 23. Other adjuncts to valproic acid for JME 
(primidone, phenytoin, ethosuximide, or felbam- 
ate) cannot be used as monotherapy without a 
risk of unacceptable side-effects 24. 
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